New approaches to the treatment of multidrug-resistant and extensively drug-resistant
tuberculosis (TB) are badly needed. Not only is the success rate of current treatment …

Background Bedaquiline and delamanid have been approved for treatment of multidrug-
resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns …

Background Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an
obstacle to treatment completion. Evaluate safety of longer MDR/RR-TB regimens …

Background Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis
and leads to serious complications if left untreated. Some strains of Mycobacterium …

Delamanid has been demonstrated to be safe and effective for treatment of adult multidrug-
resistant tuberculosis (MDR-TB) and has been approved by the European Commission for …

Background In October 2014, the World Health Organization (WHO) issued an interim policy
guidance on the use of delamanid in the treatment of patients with multidrug-resistant …

Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-resistant
(XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20 …

SETTING: The World Health Organization recommended two new drugs, bedaquiline (BDQ)
and delamanid (DLM), for the treatment of multidrug-resistant tuberculosis (MDR-TB) in …

The current treatment for drug-resistant tuberculosis (TB) is long, complex, and associated
with severe and life-threatening side effects and poor outcomes. For the first time in nearly …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) remain
significant global health challenges, with an annual incidence of approximately 480 000 and …